These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 16943394)

  • 1. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas.
    Solomon SD; Pfeffer MA; McMurray JJ; Fowler R; Finn P; Levin B; Eagle C; Hawk E; Lechuga M; Zauber AG; Bertagnolli MM; Arber N; Wittes J;
    Circulation; 2006 Sep; 114(10):1028-35. PubMed ID: 16943394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.
    Solomon SD; McMurray JJ; Pfeffer MA; Wittes J; Fowler R; Finn P; Anderson WF; Zauber A; Hawk E; Bertagnolli M;
    N Engl J Med; 2005 Mar; 352(11):1071-80. PubMed ID: 15713944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Celecoxib for the prevention of colorectal adenomatous polyps.
    Arber N; Eagle CJ; Spicak J; Rácz I; Dite P; Hajer J; Zavoral M; Lechuga MJ; Gerletti P; Tang J; Rosenstein RB; Macdonald K; Bhadra P; Fowler R; Wittes J; Zauber AG; Solomon SD; Levin B;
    N Engl J Med; 2006 Aug; 355(9):885-95. PubMed ID: 16943401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
    Bresalier RS; Sandler RS; Quan H; Bolognese JA; Oxenius B; Horgan K; Lines C; Riddell R; Morton D; Lanas A; Konstam MA; Baron JA;
    N Engl J Med; 2005 Mar; 352(11):1092-102. PubMed ID: 15713943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Celecoxib for the prevention of sporadic colorectal adenomas.
    Bertagnolli MM; Eagle CJ; Zauber AG; Redston M; Solomon SD; Kim K; Tang J; Rosenstein RB; Wittes J; Corle D; Hess TM; Woloj GM; Boisserie F; Anderson WF; Viner JL; Bagheri D; Burn J; Chung DC; Dewar T; Foley TR; Hoffman N; Macrae F; Pruitt RE; Saltzman JR; Salzberg B; Sylwestrowicz T; Gordon GB; Hawk ET;
    N Engl J Med; 2006 Aug; 355(9):873-84. PubMed ID: 16943400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer.
    Kerr DJ; Dunn JA; Langman MJ; Smith JL; Midgley RS; Stanley A; Stokes JC; Julier P; Iveson C; Duvvuri R; McConkey CC;
    N Engl J Med; 2007 Jul; 357(4):360-9. PubMed ID: 17652651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
    Sowers JR; White WB; Pitt B; Whelton A; Simon LS; Winer N; Kivitz A; van Ingen H; Brabant T; Fort JG;
    Arch Intern Med; 2005 Jan; 165(2):161-8. PubMed ID: 15668361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials.
    White WB; West CR; Borer JS; Gorelick PB; Lavange L; Pan SX; Weiner E; Verburg KM
    Am J Cardiol; 2007 Jan; 99(1):91-8. PubMed ID: 17196469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Celecoxib: new indication. Colorectal cancer: no preventive benefit.
    Prescrire Int; 2006 Feb; 15(81):13-5. PubMed ID: 16548099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients.
    Sinicrope FA; Half E; Morris JS; Lynch PM; Morrow JD; Levin B; Hawk ET; Cohen DS; Ayers GD; Stephens LC;
    Cancer Epidemiol Biomarkers Prev; 2004 Jun; 13(6):920-7. PubMed ID: 15184247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis.
    Becker MC; Wang TH; Wisniewski L; Wolski K; Libby P; Lüscher TF; Borer JS; Mascette AM; Husni ME; Solomon DH; Graham DY; Yeomans ND; Krum H; Ruschitzka F; Lincoff AM; Nissen SE;
    Am Heart J; 2009 Apr; 157(4):606-12. PubMed ID: 19332185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pilot randomized phase II study of celecoxib in oral premalignant lesions.
    Papadimitrakopoulou VA; William WN; Dannenberg AJ; Lippman SM; Lee JJ; Ondrey FG; Peterson DE; Feng L; Atwell A; El-Naggar AK; Nathan CO; Helman JI; Du B; Yueh B; Boyle JO
    Clin Cancer Res; 2008 Apr; 14(7):2095-101. PubMed ID: 18381950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical management of adenomatous polyposis in patients with hereditary non-polyposis colorectal cancer and familial adenomatous polyposis].
    Sheng JQ; Li SR; Yang XY; Zhang YH; Su H; Yu DL; Yan W; Geng HG
    Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(8):526-9. PubMed ID: 16681880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
    Huang WF; Hsiao FY; Wen YW; Tsai YW
    Clin Ther; 2006 Nov; 28(11):1827-36. PubMed ID: 17213003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Celecoxib and CVS risk--lessons from the APC and PreSAP studies.
    Armstrong DJ
    Rheumatology (Oxford); 2007 Apr; 46(4):561-2. PubMed ID: 17132690
    [No Abstract]   [Full Text] [Related]  

  • 16. Letter by Cen regarding article, "Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas".
    Cen YY
    Circulation; 2007 Mar; 115(12):e348; author reply e349. PubMed ID: 17389275
    [No Abstract]   [Full Text] [Related]  

  • 17. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study.
    Singh G; Fort JG; Goldstein JL; Levy RA; Hanrahan PS; Bello AE; Andrade-Ortega L; Wallemark C; Agrawal NM; Eisen GM; Stenson WF; Triadafilopoulos G;
    Am J Med; 2006 Mar; 119(3):255-66. PubMed ID: 16490472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risks and benefits of celecoxib to prevent recurrent adenomas.
    Psaty BM; Potter JD
    N Engl J Med; 2006 Aug; 355(9):950-2. PubMed ID: 16943408
    [No Abstract]   [Full Text] [Related]  

  • 19. Blood pressure in Native Americans switched from celecoxib to rofecoxib.
    Fredy J; Diggins DA; Morrill GB
    Ann Pharmacother; 2005 May; 39(5):797-802. PubMed ID: 15797981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The safety and efficacy of celecoxib in children with familial adenomatous polyposis.
    Lynch PM; Ayers GD; Hawk E; Richmond E; Eagle C; Woloj M; Church J; Hasson H; Patterson S; Half E; Burke CA
    Am J Gastroenterol; 2010 Jun; 105(6):1437-43. PubMed ID: 20234350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.